Stock Movers on FDA Decision (IHNX, ISIS, AGN, STEM)

Inhibitex, Inc. (NASDAQ:INHX) climbed 6.34% to $1.51 on heavy volume after the company announces the successful completion of INX-189 phase 1a. INX-189 is a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. Preliminary data from 42 healthy volunteers receiving INX-189 or a placebo.

Inhibitex, Inc. is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent and treat serious infections.

You can Subscribe to these  Free Stock Alerts  by visiting:  http://www.pennystockpickreport.com/

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) climbed 1.66% to $7.94 on heavy volume after it and Isis Pharmaceuticals Inc. (Nasdaq: ISIS) announce the presentation of data from a phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH).

Data was presented at European Society of Cardiology’s Congress 2010 in Stockholm, Sweden.

GENZ and ISIS say that the study met with its primary endpoint, which was a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo (p<0.001).

Allergan, Inc. (NYSE:AGN) rose 2.10% to $62.70 after it receives U.S. FDA approval for LUMIGAN 0.01% as a first-line therapy indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

LUMIGAN 0.01% is a once-daily prescription eye drop that provides effective and sustained IOP lowering.

StemCells, Inc. (NASDAQ:STEM) jumped 2.53% to $0.770 on higher than the acerage volume after it announces that they have created the first genetically engineered rat derived from rat embryonic stem (ES) cells. Data from the study will be published this month in the international peer-reviewed journal Nature.

The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.

About http://www.pennystockpickreport.com/

Penny Stock Pick Report offers stock newsletter on OTC, PINKSHEETS ,OTCBB, AMEX, NASDAQ and NYSE stock exchange. Our subscribers receive daily up to date stock information on hot stocks, most active movers, top gainers, penny stocks and much more. If you wish to feature your organization on our website then you can contact us at the email given below.